<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="632">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152927</url>
  </required_header>
  <id_info>
    <org_study_id>21208</org_study_id>
    <secondary_id>5R01CA212147-02</secondary_id>
    <nct_id>NCT05152927</nct_id>
  </id_info>
  <brief_title>Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy</brief_title>
  <official_title>Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to assess whether using PTeye (AiBiomed, Santa Barbara, CA) - a&#xD;
      NIRAF detection modality - can improve patient outcomes and reduce healthcare associated&#xD;
      costs after parathyroid surgeries. By being able to quickly and definitively locate&#xD;
      parathyroid glands while in the operating room, the duration of surgical procedure could be&#xD;
      further reduced. In addition, the number of frozen section biopsy and associated costs can be&#xD;
      minimized. Furthermore, repeat surgeries as a result of missing a diseased parathyroid gland&#xD;
      at the time of the initial parathyroidectomy for hyperparathyroidism could potentially be&#xD;
      avoided.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-blinded, randomized study comparing the use of PTeye during&#xD;
      parathyroidectomy to usual standard practice.&#xD;
&#xD;
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the impact of PTeye on intra-operative identification of parathyroid tissues.&#xD;
&#xD;
      II. Assess the impact of PTeye on improving efficiency of parathyroid surgeries.&#xD;
&#xD;
      III. Assess the impact of PTeye on minimizing risk of post-surgical complications.&#xD;
&#xD;
      Participants will be randomized to either the experimental or control arm.&#xD;
&#xD;
      The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck&#xD;
      muscles, if thyroid is absent) using the disposable sterile fiber probe that is connected to&#xD;
      the PTeye console, as per device functionality requirements. The subsequent step would&#xD;
      involve touching the target tissue in the neck with the fiber optic probe, following which&#xD;
      the PTeye will indicate to the surgeon if the tissue is likely parathyroid or not.&#xD;
&#xD;
      For patients assigned to the control arm, the surgeon will not use the PTeye and will proceed&#xD;
      with the parathyroid surgery as usual, while relying solely on her/his surgical experience in&#xD;
      identifying the parathyroid glands during the operations.&#xD;
&#xD;
      Participants will be follow-ed up for up to 6 months after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Only participants will be masked to the intervention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Median number of frozen sections (or PTH aspirate) sent for analysis</measure>
    <time_frame>1 day</time_frame>
    <description>Number of frozen sections (or PTH aspirate) sent for analysis during the Parathyroidectomy (PTx) procedure to confirm potential parathyroid tissue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with persistent hyperparathyroidism (Immediate)</measure>
    <time_frame>1 day</time_frame>
    <description>Failure of intra-operative parathyroid hormone (PTH) to normalize (defined as failure of PTH to drop &gt; 50% of its baseline value at final intra-operative PTH assay and/or failure of PTH to drop &lt; 65 pg/ml or 6.9 pmol/L). Participants will be categorized as having persistent hyperparathyroidism (Immediate) Yes or No.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with persistent hyperparathyroidism or hypercalcemia (transient)</measure>
    <time_frame>5-14 days after PTx procedure</time_frame>
    <description>Elevated blood calcium levels (total blood calcium level &gt; 10.5 mg/dL or 2.6 mmol/L) with/without elevated parathyroid hormone (PTH) (serum intact PTH &gt; 65 pg/ml or 6.9 pmol/L) at first postoperative visit. Participants will be categorized as having persistent hyperparathyroidism or hypercalcemia (transient) Yes or No.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants persistent hyperparathyroidism or hypercalcemia (failed parathyroidectomy)</measure>
    <time_frame>Up to 6 months after PTx procedure</time_frame>
    <description>If blood calcium with/without parathyroid hormone (PTH) has not normalized at 1st post-operative visit, calcium and/or PTH is subsequently measured as necessary. Patient is defined to have a failed parathyroidectomy if hypercalcemia/hyperparathyroidism (defined as total blood calcium level &gt; 10.5 mg/dL or 2.6 mmol/L, with/without elevated serum intact PTH &gt; 65 pg/ml or 6.9 pmol/L) persists at or after the 6th postoperative month. Participants will be categorized has having persistent hyperparathyroidism or hypercalcemia (failed parathyroidectomy), Yes or No.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of parathyroid glands (PG) identified</measure>
    <time_frame>1 day</time_frame>
    <description>Overall number of parathyroid glands identified (Experimental Group: Glands identified with naked eye + NIRAF;Control Group: Glands identified with naked eye)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of parathyroid glands identified with NIRAF</measure>
    <time_frame>1 day</time_frame>
    <description>Median number of parathyroid glands identified with NIRAF, which was not seen with surgeon's naked eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of diseased parathyroid glands identified versus preoperatively localized glands</measure>
    <time_frame>1 day</time_frame>
    <description>Median number of diseased parathyroid glands identified intra-operatively versus glands localized preoperatively using sestamibi, Computerized tomography (CT) or ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of intra-operative parathyroid hormone (PTH) assays sent</measure>
    <time_frame>1 day</time_frame>
    <description>Median number of intra-operative parathyroid hormone assays per person sent during the procedure to the lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration taken to identify first parathyroid gland</measure>
    <time_frame>1 day</time_frame>
    <description>Median duration in minutes taken to identify 1st parathyroid gland in PTx procedure - timed from skin incision to finding PG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration taken to identify last parathyroid gland</measure>
    <time_frame>1 day</time_frame>
    <description>Median duration taken to identify last parathyroid gland in PTx procedure - timed from skin incision to finding the last PG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of parathyroidectomy (PTx) procedure</measure>
    <time_frame>1 day</time_frame>
    <description>Median duration of PTx procedure - timed from skin incision until the surgeon notifies the anesthesia team to awaken the patient in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration for intraoperative parathyroid hormone (PTH) to normalize</measure>
    <time_frame>1 day</time_frame>
    <description>Median time in minutes taken for PTH to attain cure criteria or normalize - timed from skin incision until the PTH levels drops &gt; 50% of its baseline value and/or PTH drops &lt; 65 pg/ml or 6.9 pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of nights spent in the hospital after parathyroidectomy</measure>
    <time_frame>0-72 hours after PTx procedure</time_frame>
    <description>Number of nights spent for postoperative recovery in the hospital after the surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of 'false positive' tissues excised by surgeon</measure>
    <time_frame>Up to 10 days after PTx procedure</time_frame>
    <description>Median number of tissues per person that were excised by surgeon assumed to be parathyroid tissue, but is later validated as nonparathyroid tissue (false positive) by histology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reported doctor visits/emergency department visits or hospital admissions</measure>
    <time_frame>Up to 6 months after PTx procedure</time_frame>
    <description>Number of doctor visits/emergency department visits or hospital admissions due to persistent hypercalcemia and/or associated symptoms after parathyroidectomy procedure will be categorized as binary (yes or no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who have had repeat parathyroidectomy (PTx) procedure</measure>
    <time_frame>From 6 - 12 months after PTx procedure</time_frame>
    <description>Number of patients with repeat PTx procedure performed after the current procedure will be categorized as binary (yes or no)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Parathyroid Diseases</condition>
  <condition>Parathyroid Dysfunction</condition>
  <condition>Parathyroid Neoplasms</condition>
  <condition>Parathyroid Adenoma</condition>
  <condition>Hypercalcemia</condition>
  <condition>Neoplasms, Glandular and Epithelial</condition>
  <condition>Endocrine Gland Neoplasms</condition>
  <condition>Adenoma</condition>
  <condition>Hyperparathyroidism</condition>
  <condition>Hyperparathyroidism, Primary</condition>
  <arm_group>
    <arm_group_label>Parathyroid Eye (PTeye)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Parathyroid Eye (PTeye)</intervention_name>
    <description>Intraoperative Tool</description>
    <arm_group_label>Parathyroid Eye (PTeye)</arm_group_label>
    <other_name>Near Infrared Autofluorescence (NIRAF)</other_name>
    <other_name>NIRAF detection modality</other_name>
    <other_name>PTeye</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adults &gt;=18 years old) patients with primary hyperparathyroidism who will be&#xD;
             undergoing parathyroid surgery&#xD;
&#xD;
          -  All adult (&gt;=18 years old) patients with persistent primary hyperparathyroidism after&#xD;
             having undergone a failed prior parathyroid surgery who will be undergoing repeat&#xD;
             parathyroid surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children and minors&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patients with concurrent parathyroid and thyroid disease that require total&#xD;
             thyroidectomy&#xD;
&#xD;
          -  Patients with secondary or tertiary hyperparathyroidism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quan-Yang Duh, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Foft</last_name>
    <phone>(415) 476-2816</phone>
    <email>Jessica.Foft@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jessica Foft</last_name>
      <phone>415-476-2816</phone>
      <email>Jessica.Foft@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Quan-Yang Duh, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McWade MA, Paras C, White LM, Phay JE, Mahadevan-Jansen A, Broome JT. A novel optical approach to intraoperative detection of parathyroid glands. Surgery. 2013 Dec;154(6):1371-7; discussion 1377. doi: 10.1016/j.surg.2013.06.046.</citation>
    <PMID>24238054</PMID>
  </reference>
  <reference>
    <citation>Thomas G, Sol√≥rzano CC, Baregamian N, Mannoh EA, Gautam R, Irlmeier RT, Ye F, Nelson JA, Long SE, Gauger PG, Magner A, Metcalf T, Shirley LA, Phay JE, Mahadevan-Jansen A. Comparing intraoperative parathyroid identification based on surgeon experience versus near infrared autofluorescence detection - A surgeon-blinded multi-centric study. Am J Surg. 2021 May 13. pii: S0002-9610(21)00280-4. doi: 10.1016/j.amjsurg.2021.05.001. [Epub ahead of print]</citation>
    <PMID>34024629</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Near Infrared Autofluorescence</keyword>
  <keyword>Parathyroidectomy</keyword>
  <keyword>Intraoperative Parathyroid Identification</keyword>
  <keyword>Persistent Hyperparathyroidism</keyword>
  <keyword>Persistent Hypercalcemia</keyword>
  <keyword>Failed Parathyroidectomy</keyword>
  <keyword>Repeat Parathyroidectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Parathyroid Diseases</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parathyroid Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

